CN114007603A - 用于使用大麻素进行神经保护的组合物和方法 - Google Patents

用于使用大麻素进行神经保护的组合物和方法 Download PDF

Info

Publication number
CN114007603A
CN114007603A CN202080046190.4A CN202080046190A CN114007603A CN 114007603 A CN114007603 A CN 114007603A CN 202080046190 A CN202080046190 A CN 202080046190A CN 114007603 A CN114007603 A CN 114007603A
Authority
CN
China
Prior art keywords
neuroprotective
compound
composition
neuroprotective compound
neuron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080046190.4A
Other languages
English (en)
Chinese (zh)
Inventor
E·徐
U·库马
R·K·索姆万施
S·邹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inmed Pharmaceuticals Inc
Original Assignee
Inmed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc
Publication of CN114007603A publication Critical patent/CN114007603A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080046190.4A 2019-04-24 2020-04-24 用于使用大麻素进行神经保护的组合物和方法 Pending CN114007603A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
US62/838216 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (1)

Publication Number Publication Date
CN114007603A true CN114007603A (zh) 2022-02-01

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046190.4A Pending CN114007603A (zh) 2019-04-24 2020-04-24 用于使用大麻素进行神经保护的组合物和方法

Country Status (11)

Country Link
US (1) US20230043428A1 (https=)
EP (1) EP3958856A4 (https=)
JP (1) JP7633179B2 (https=)
KR (1) KR20220080045A (https=)
CN (1) CN114007603A (https=)
AU (1) AU2020261515B2 (https=)
CA (1) CA3134764A1 (https=)
IL (1) IL287536B2 (https=)
MX (1) MX2021012960A (https=)
SG (1) SG11202111809XA (https=)
WO (1) WO2020215164A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024091653A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions
WO2025090133A1 (en) * 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160250270A1 (en) * 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
WO2018061007A1 (en) * 2016-09-29 2018-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Dilutable formulations of cannabinoids and processes for their preparation
US20180098948A1 (en) * 2016-10-11 2018-04-12 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
CN108027353A (zh) * 2015-03-28 2018-05-11 帝肯样品制备股份有限公司 固相萃取、用冠醚衍生化、以及质谱、方法、试剂和试剂盒
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
WO2018205022A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2640379A4 (en) * 2010-11-18 2014-08-13 Pier Pharmaceuticals LOW DOSED CANNABINOIDARY MEDICINES
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160250270A1 (en) * 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
CN108027353A (zh) * 2015-03-28 2018-05-11 帝肯样品制备股份有限公司 固相萃取、用冠醚衍生化、以及质谱、方法、试剂和试剂盒
WO2018061007A1 (en) * 2016-09-29 2018-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Dilutable formulations of cannabinoids and processes for their preparation
US20180098948A1 (en) * 2016-10-11 2018-04-12 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
WO2018205022A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张开镐: "大麻的生物学效应(二)", 中国药物依赖性杂志, no. 02, 28 May 2003 (2003-05-28), pages 94 - 96 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用

Also Published As

Publication number Publication date
IL287536A (en) 2021-12-01
AU2020261515A1 (en) 2021-11-18
WO2020215164A1 (en) 2020-10-29
EP3958856A4 (en) 2023-01-25
IL287536B2 (en) 2026-03-01
US20230043428A1 (en) 2023-02-09
SG11202111809XA (en) 2021-11-29
IL287536B1 (en) 2025-11-01
JP2022530471A (ja) 2022-06-29
JP7633179B2 (ja) 2025-02-19
AU2020261515B2 (en) 2025-10-23
KR20220080045A (ko) 2022-06-14
EP3958856A1 (en) 2022-03-02
MX2021012960A (es) 2022-01-04
CA3134764A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
JP7633179B2 (ja) 神経保護のためのカンナビノイドの組成物及び使用方法
KR20100016140A (ko) 가령 황반 변성의 예방 또는 치료제
Zhang et al. Ultra-small nanocomplexes based on polyvinylpyrrolidone K-17PF: A potential nanoplatform for the ocular delivery of kaempferol
US9694010B2 (en) Therapeutic formulation and methods of treatment
ES2324130B1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular.
RU2672057C2 (ru) Ингибитор хориоретинальных нарушений
CA3164071A1 (en) Compounds for treatment of alzheimer's disease
Saxena et al. Pharmacotherapy of glaucoma
CN106999452B (zh) 前列腺素类和一氧化氮供体的组合产品
CN117136050A (zh) 用于使用大麻素治疗神经元病症的组合物和方法
WO2008150954A1 (en) Treatment of age-related macular degeneration
EP1280528B1 (en) R-eliprodil for treating glaucoma
EP1859795A1 (en) Therapeutic agent for ophthalmic disease
WO2025090133A1 (en) Compositions and methods for use of cannabinol compounds in neuroprotection
AU2013332731A1 (en) Methods for treating eye disorders
US20080318939A1 (en) Methods for treating ophthalmic disorders
WO2009110526A1 (ja) ３’，５－ジ－２－プロペニル－（１，１’－ビフェニル）－２，４’－ジオールを有効成分として含有する視神経障害の予防又は治療剤
WO2025090587A1 (en) Cannabinoids compounds and their use in the treatment of neuronal disorders
WO2020166679A1 (ja) 眼圧下降用医薬組成物
JP2023042650A (ja) 眼科用剤
Kobayashi et al. 152. Neuroprotection Organizing Section: PH Contributing Section: RC
US20030212107A1 (en) R-reliprodil for treating glaucoma
HK1241269B (zh) 前列腺素类和一氧化氮供体的组合产品

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination